Shanghai, July 18 - China-Biotics, Inc., a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has applied for listing approval on the Nasdaq Global Market.
"This is an important milestone for China-Biotics, and we are committed to working with Nasdaq to fulfill all of its listing requirements," said Mr. Jinan Song, China-Biotics' Chairman and Chief Executive Officer. "Nasdaq is a prestigious senior exchange that is well suited for high-technology and high-growth companies such as China-Biotics that meet its stringent listing requirements. Nasdaq's complement of small-cap, rapidly growing companies will increase our visibility among investors who follow companies like ours, improving trading volume and liquidity. This should, in turn, attract new investors to our Company."
China-Biotics believes it satisfies all of the listing qualifications associated with this application. The application is subject to review by Nasdaq's Listing Qualifications Department for compliance with all Nasdaq Global Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CHBT, until the Company is notified of its acceptance. We hope to receive approval to list on Nasdaq within two to three months.